PHIO

Phio Pharmaceuticals Corp. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website iopharma.com
Employees(FY) 9
ISIN US71880W5013

Performance

-7.03%

-18.21%

-23.23%

-66.39%

-65.2%

YTD

-74.07%

Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Advanced Technical Analysis

Technical Analysis of PHIO 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market shows limited bu...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PHIO

Stock Rank

Recent News & Updates

2024-11-18 18:45
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study(Newsfilecorp)
2024-11-14 04:47
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update(Newsfilecorp)
2024-11-06 21:00
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)(Newsfilecorp)
2024-10-31 19:45
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series(Newsfilecorp)
2024-10-23 20:00
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)(Newsfilecorp)
2024-10-18 01:30
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series(Newsfilecorp)
2024-10-17 20:00
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series(Newsfilecorp)
2024-10-15 20:00
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference(Newsfilecorp)
2024-10-06 20:00
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells(Newsfilecorp)
2024-10-01 16:00
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series(Newsfilecorp)
2024-09-30 20:00
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference(Newsfilecorp)
2024-09-24 20:00
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society(Newsfilecorp)
2024-09-16 20:00
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series(Newsfilecorp)
2024-09-15 20:00
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA(Newsfilecorp)
2024-09-08 19:00
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Newsfilecorp)
2024-08-28 20:30
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series(Newsfilecorp)
2024-08-14 05:00
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update(Newsfilecorp)
2024-08-05 20:00
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound(Newsfilecorp)
2024-07-31 20:00
Phio Pharmaceuticals Announces New Chief Financial Officer(Newsfilecorp)
2024-07-11 20:00
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds(Newsfilecorp)
2024-07-07 20:00
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762(Newsfilecorp)
2024-07-04 20:00
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds(Newsfilecorp)
2024-07-01 23:45
Phio Pharmaceuticals Announces Reverse Stock Split(Newsfilecorp)
2024-06-17 19:30
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging(Newsfilecorp)
2024-05-27 19:30
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762(Newsfilecorp)
2024-05-23 05:00
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)(Newsfilecorp)
2024-05-16 21:00
Phio Pharmaceuticals Secures New Investor(Globenewswire)
2024-05-15 20:00
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)(Globenewswire)
2024-05-15 01:00
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study(Globenewswire)
2024-05-09 11:53
PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024(Investorplace)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.